Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4861089 | 0.83 | ALDH1A1 (0.58) | CNR1CNR2TRPV1P2RX7BDKRB1 | |
| SCHEMBL7469538 | 0.81 | ALDH1A1 (0.46) | CNR1CNR2 | |
| SCHEMBL4226632 | 0.81 | TRPV1 (0.54) | CNR1CNR2TRPV1BRD4CREBBP | |
| SCHEMBL4226634 | 0.81 | TRPV1 (0.54) | CNR1CNR2TRPV1BRD4CREBBP | |
| SCHEMBL22454626 | 0.80 | HSD17B10 (0.50) | CNR1CNR2TRPV1P2RX7BRD4 | |
| SCHEMBL600126 | 0.80 | DRD2 (0.49) | CNR1CNR2TRPV1P2RX7BDKRB1 | |
| SCHEMBL600125 | 0.80 | DRD2 (0.49) | CNR1CNR2TRPV1P2RX7BDKRB1 | |
| SCHEMBL27125516 | 0.79 | TRPV1 (0.50) | CNR1CNR2TRPV1BRD4CREBBP | |
| SCHEMBL26962614 | 0.79 | TRPV1 (0.50) | CNR1CNR2TRPV1BRD4CREBBP | |
| SCHEMBL20622055 | 0.78 | TRPV1 (0.49) | CNR1CNR2TRPV1P2RX7BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | CNR1 625/4885CNR2 841/4885TRPV1 232/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | CNR1 769/4885CNR2 998/4885TRPV1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.